Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Pressure BioSciences, Inc.    PBIO

PRESSURE BIOSCIENCES, INC.

(PBIO)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

PRESSURE BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)

share with twitter share with LinkedIn share with facebook
06/29/2020 | 05:25pm EDT

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, forward-looking statements are identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" and similar expressions intended to identify forward-looking statements. Such statements include, without limitation, statements regarding:



    ?   our need for, and our ability to raise, additional equity or debt
        financing on acceptable terms, if at all;
    ?   our need to take additional cost reduction measures, cease operations or
        sell our operating assets, if we are unable to obtain sufficient
        additional financing;
    ?   our belief that we will have sufficient liquidity to finance normal
        operations for the foreseeable future;
    ?   the options we may pursue in light of our financial condition;
    ?   the potential applications for Ultra Shear Technology (UST);
    ?   the potential applications of the BaroFold high-pressure protein refolding
        and disaggregation technology
    ?   the amount of cash necessary to operate our business;
    ?   the anticipated uses of grant revenue and the potential for increased
        grant revenue in future periods;
    ?   our plans and expectations with respect to our continued operations;
    ?   the expected increase in the number of pressure cycling technology ("PCT")
        and constant pressure ("CP") based units that we believe will be installed
        and the expected increase in revenues from the sale of consumable
        products, extended service contracts, and biopharma contract services;
    ?   our belief that PCT has achieved initial market acceptance in the mass
        spectrometry and other markets;
    ?   the expected development and success of new instrument and consumables
        product offerings;
    ?   the potential applications for our instrument and consumables product
        offerings;
    ?   the expected expenses of, and benefits and results from, our research and
        development efforts;
    ?   the expected benefits and results from our collaboration programs,
        strategic alliances and joint ventures;
    ?   our expectation of obtaining additional research grants from the
        government in the future;
    ?   our expectations of the results of our development activities funded by
        government research grants;
    ?   the potential size of the market for biological sample preparation,
        biopharma contract services and ultra shear technology;
    ?   general economic conditions;
    ?   the anticipated future financial performance and business operations of
        our company;
    ?   our reasons for focusing our resources in the market for genomic,
        proteomic, lipidomic and small molecule sample preparation;
    ?   the importance of mass spectrometry as a laboratory tool;
    ?   the advantages of PCT over other current technologies as a method of
        biological sample preparation and protein characterization in biomarker
        discovery, forensics, and histology, as well as for other applications;
    ?   the capabilities and benefits of our PCT Sample Preparation System,
        consumables and other products;
    ?   our belief that laboratory scientists will achieve results comparable with
        those reported to date by certain research scientists who have published
        or presented publicly on PCT and our other products and services;
    ?   our ability to retain our core group of scientific, administrative and
        sales personnel; and
    ?   our ability to expand our customer base in sample preparation and for
        other applications of PCT and our other products and services.



These forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements, expressed or implied, by such forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial and other results include those discussed in the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019 and in this Report. We qualify all of our forward-looking statements by these cautionary statements.



26







                                   OVERVIEW:


We are a leader in the development and sale of innovative, broadly enabling, pressure-based platform solutions for the worldwide life sciences industry. Our solutions are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus has been in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology platform) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be acceptably preserved using existing non-thermal technologies.

On April 29, 2020, we signed a binding letter of intent to merge with Cannaworx, Inc. (USA), and their portfolio of products and intellectual property (the "Cannaworx LOI" and "Cannaworx merger"). Cannaworx founders Bobby Ghalili, DMD and Adrienne Denese, MD, PhD bring extensive medical expertise and product innovation into the newly combined public company. Post-merger, Cannaworx products will utilize our proprietary UST platform.

Subsequently, we announced two letters of intent by Cannaworx which we will assume in the Cannaworx merger. On April 30, 2020 we announced a signed Cannaworx agreement to acquire SkinScience Labs, Inc or "SSL" (the SSL LOI). SSL is the parent company of Dr. Denese's skin care and anti-aging product lines. Subsequently, on May 7, 2020 we announced a signed Cannaworx agreement to acquire Five Leaf Labs or "FFL" (the FLL LOI). FLL is based in Louisiana and will expand the Cannaworx sales and distribution network to over 50 sales representatives in 21 states.

The Cannaworx LOI and SSL LOI are subject to certain closing conditions, including completion of all due diligence and acquisition financing. The FLL LOI is subject to the completion of all due diligence.

On May 7, 2020 we also announced that, if the mergers are completed, Jim Morrison would be appointed as the new CEO of the rebranded public company and that following the completion of the Cannaworx merger we would change our name to "Availa Bio".



27






Developments and Accomplishments:

We reported the following accomplishments during the first quarter, April and May 2020:

On May 14, 2020, Pressure BioSciences announced the launch of FDA-registered hand sanitizer as first product developed through pending merger partners.

On May 7, 2020, former L'Oreal President Jim Morrison, one of the top brand strategists in the personal care space worldwide, was announced as the person who would become CEO of Availa Bio upon merger completion.

On May 5, 2020, PBI announced plans to change name to Availa Bio following completion of the Cannaworx and SkinScience Labs merger.

On April 30, 2020, PBI announced plans to acquire SkinScience Labs and their profitable and award-winning Dr. Denese Skin Care and Anti-Aging Lines.

On April 29, 2020, PBI announced plans to acquire Cannaworx, Inc. and their portfolio of innovative consumer products.

On April 16, 2020, PBI and RedShiftBio demonstrate potential of combining proprietary technologies to enable new tool for development and production of biotherapeutics.

On March 12, 2020, PBI announced that it is nearing a complete sellout on its pre-launch offering of game-changing UST Platform for processing CBD Oil into water-soluble nanoemulsions.

On February 27, 2020, PBI launched new era in preparation of water-soluble nanoemulsions for CBD and other valuable oils with opening of UST Demonstration Laboratory.

On January 30, 2020, PBI announced acceleration of UST Platform rollout for water-soluble CBD with planned release of additional BaroShear product - a benchtop, R&D scale, BaroShear 'Mini" instrument.

On January 24, 2020, PBI announced significant new order and near sellout on revolutionary nanoemulsification system for water-soluble CBD oil. Company said that additional orders are expected shortly.

On January 17, 2020, PBI reported the Company's UST Platform was featured in a leading North American Cannabis Magazine and that the article highlighted the potential of the UST Platform to play a significant role in multiple billion-dollar markets, such as CBD, nutraceuticals, cosmetics, biopharmaceuticals, and food/beverage.

On January 9, 2020, PBI reported that the number of published scientific papers in 2019 citing the advantages of the Company's PCT Platform remained strong, with over 20 journal articles for the second straight year.



Results of Operations


Quarter ended March 31, 2020 ("Q1 2019") as compared with March 31, 2019 ("Q1 2019")

Products, Services, and Other Revenue

We recognized total revenue of $253,873 for Q1 2020 compared to $510,240 for Q1 2019, a decrease of $256,367 or 50%. This decrease was primarily attributable to a $228,199 decrease in Scientific Services revenue which was primarily attributable to the negative impact that the COVID-19 pandemic had on our operations and on the operations of our customers.



28







Cost of Products and Services


The cost of products and services was $175,146 for the three months ended March 31, 2020 compared to $309,712 for the comparable period in 2019. Gross profit margin on products and services decreased to 31% for Q1 2020 compared to 39% for the prior year period. The current period margin was affected by the reduction in higher-margin Scientific Services revenue.



Research and Development


Research and development expenditures were $265,690 during the three months ended March 31, 2020 as compared to $264,704 in the same period in 2019, an increase of $986 or 0.4%.



Selling and Marketing


Selling and marketing expenses were $189,116 for the three months ended March 31, 2020 from $188,215 for the comparable period in 2019, an increase of $901.



General and Administrative


General and administrative costs totaled $1,019,010 for Q1 2020 compared to $1,144,421 for the comparable period in 2019.This decrease was principally related to lower investor relations and stock based compensation expenses.



29







Operating Loss


Operating loss was $1,395,089 for the three months ended March 31, 2020 compared to $1,396,812 for the comparable period in 2019. This decrease was principally attributable to lower operating costs and expenses, which offset the $256,367 decrease in revenues.




Interest Expense, net



Interest expense was $1,571,800 for the three months ended March 31, 2020 compared to interest expense of $512,706 for the three months ended March 31, 2019. The increase in interest expense is directly attributable to the increase in convertible and other debt.

(Loss) on extinguishment of liabilities

In connection with payments of interest in common stock and debt extensions, we recognized losses of $1,136,367 in the quarter ended March 31, 2020 and losses of $40,810 in the quarter ended March 31, 2019. This increase was related to extension fees incurred and warrants issued for the recent amendments to Standstill and Forbearance Agreements and merchant loan extension.



Net Loss


During the quarter ended March 31, 2020 we recorded net loss attributable to common shareholders $4,278,471 or ($1.62) per share, as compared with $3,470,982 or ($2.01) per share during the quarter ended March 31, 2019. The decrease in the loss per share was attributable a 54% increase in weighted shares outstanding.

Liquidity and Financial Condition

We have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of March 31, 2020, we did not have adequate working capital resources to satisfy our current liabilities and as a result, we have substantial doubt regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings in the past and as described in Notes 4 and 5 of the accompanying consolidated financial statements, we received $2.3 million in net proceeds from loans in the first three months of 2020. We have efforts in place to continue to raise cash through debt and equity offerings.

We will need substantial additional capital to fund our operations in future periods. If we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects.

Net cash used in operations for the three months ended March 31, 2020 was $1,364,639 as compared to $1,617,924 for the three months ended March 31, 2019.

Net cash used in investing activities for the three months ended March 31, 2020 was $0 as compared to $12,615 for the three months ended March 31, 2019.

Net cash provided by financing activities for the three months ended March 31, 2020 was $1,366,833 as compared to $1,797,135 for the same period in the prior year. The cash flow from financing activities of the three months ended March 31, 2019 included $1,260,000 of proceeds from the sale of preferred stock which did not recur in 2020. This decrease was offset by a increase in net convertible debt borrowings.

30

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
Latest news on PRESSURE BIOSCIENCES, INC.
07/08PRESSURE BIOSCIENCES INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
07/07PRESSURE BIOSCIENCES : First Quarter 2020 Financial and Business Update to Inclu..
PR
06/29PRESSURE BIOSCIENCES : Management's Discussion and Analysis of Financial Conditi..
AQ
06/12Pressure BioSciences' $3.5 Million Order for Hand Sanitizer is a Major Indica..
NE
06/11PRESSURE BIOSCIENCES : $3,500,000 Initial Order for FDA-Registered, Premium Hand..
PR
05/19PRESSURE BIOSCIENCES : Pending Merger Partner Cannaworx, Inc. Announces Letter o..
PR
05/15PRESSURE BIOSCIENCES INC : Other Events (form 8-K)
AQ
05/04Pressure BioSciences' Recently Announced Acquisitions Advance the Company For..
NE
04/14PRESSURE BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
03/12PRESSURE BIOSCIENCES : Nearing Complete Sellout on Pre-launch Offering of Game-C..
PR
More news
Financials (USD)
Sales 2020 5,81 M - -
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 6,26 M 6,26 M -
EV / Sales 2019
Capi. / Sales 2020 1,08x
Nbr of Employees -
Free-Float 93,9%
Chart PRESSURE BIOSCIENCES, INC.
Duration : Period :
Pressure BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 4,44 $
Last Close Price 1,90 $
Spread / Highest target 134%
Spread / Average Target 134%
Spread / Lowest Target 134%
Managers
NameTitle
Richard T. Schumacher President, CEO, Treasurer & Director
Jeffrey N. Peterson Chairman
Edmund Y. Ting Senior Vice President-Engineering
Alexander V. Lazarev Chief Science Officer
Vito J. Mangiardi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PRESSURE BIOSCIENCES, INC.52.00%6
MEDTRONIC PLC-16.57%126 954
BAXTER INTERNATIONAL INC.1.23%43 073
DEXCOM, INC.87.59%37 893
HOYA CORPORATION3.54%37 814
TERUMO CORPORATION1.93%27 852